Abstract
Aims
To compare the efficacy and tolerability of Oxymetazoline 0.05 % plus Dexpanthanol 5% versus Xylometazoline 0.1 % nasal drops in patients with nasal congestion due to allergic rhinitis and following nasal surgery.
Methods
An investigator-blind, randomized, controlled, phase IV clinical trial conducted in 100 patients with acute allergic rhinitis or patients post-nasal surgery. Patients received either Oxymetazoline 0.05% with Dexpanthanol 5% (OD) or Xylometazoline 0.1% (XO) nasal drops.
Results
Relief from nasal congestion was significantly better in the OD group then in the XO group (mean nasal scores 1.24 vs 1.86). Significantly more improvement in sneezing and decrease in nasal discharge was seen in the OD group than the XO group. Nasal irritation in the OD group was significantly less as compared to XO group (0.38 v/s 1.12 on second day and 0.10 vs 0.36 on the fourth day). The recovery time for OD group was 1.08 hours, which was significantly (46 min) lesser than that of the XO group. Rebound congestion was significantly less in OD as compared to XO group (6.25% vs 82.98%). 93.75% of the physicians in the OD group and 51.28% in XO group reported response to therapy as good to excellent. 95.83% patients in the OD group and only 52.91% patients in the XO group rated tolerability to therapy as good to excellent.
Conclusion
Oxymetazoline and dexpanthenol combination has a better efficacy, shorter recovery time, causes lesser rebound congestion and has better tolerability than xylometazoline.
Key words: Oxymetazoline, dexpanthenol, xylometazoline, rebound congestion
Full Text
The Full Text of this article is available as a PDF (484.1 KB).
References
- 1.Kehrl W., Sonnemann U., Dethlefsen U. Advance in therapy of acute rhinitis-comparison of efficacy and safety of xylometazoline in combination xylometazolinedexpanthenol in patients with acute rhinitis. Laryngorhinootologie. 2003;82(4):266–71. doi: 10.1055/s-2003-38941. [DOI] [PubMed] [Google Scholar]
- 2.Kehrl W., Sonnemann U. Improving wound healing after nose surgery by combined administration of xylometazoline and dexpanthenol. Laryngorhinootologie. 2000;79(3):151–4. doi: 10.1055/s-2000-295. [DOI] [PubMed] [Google Scholar]
- 3.Hosemann W., Wigand M.E., Gode U., Langer F., Dunker I. Normal wound healing of the paranasal sinuses: clinical and experimental investigations. Eur Arch Otorhinolaryngol. 1991;248(7):390–4. doi: 10.1007/BF01463560. [DOI] [PubMed] [Google Scholar]
- 4.Klocker N., Verse T., Rudolph P. The protective effect of dexpanthenol in nasal sprays. First results of cytotoxic and ciliary-toxic studies in vitro. Laryngorhinootologie. 2003;82(3):177–82. doi: 10.1055/s-2003-38406. [DOI] [PubMed] [Google Scholar]
- 5.Klocker N., Rudolph P., Verse T. Evaluation of protective and therapeutic effects of dexpanthenol on nasal decongestants and preservatives: results of cytotoxic studies in vitro. Am J Rhinol. 2004;18(5):315–20. [PubMed] [Google Scholar]
- 6.Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Goodman & Gilman’s. The Pharmacological Basis Of Therapeutics. Eleventh Edition. Page 262
- 7.Tuettenberg A., Koelsch S., Knop J., Jonuleit H. Oxymetazoline modulates proinflammatory cytokines and the T-cell stimulatory capacity of dendritic cells. Exp Dermatol. 2007;16(3):171–8. doi: 10.1111/j.1600-0625.2006.00527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dorn M., Hofmann W., Knick E. Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis. HNO. 2003;51(10):794–9. doi: 10.1007/s00106-003-0869-z. [DOI] [PubMed] [Google Scholar]
- 9.Westerveld G.J., Scheeren R.A., Dekker I., Griffioen D.H., Voss H.P., Bast A. Antioxidant actions of oxymethazoline and xylomethazoline. Eur J Pharmacol. 1995;291(1):27–31. doi: 10.1016/0922-4106(95)90185-x. [DOI] [PubMed] [Google Scholar]